**Title:** Antibody-Drug-Grafted Immune Cells

**Invention:** This invention includes immune cells that are combined with antibody-drug conjugates. The inventors created a quick one-step method that immediately modifies immune cells with antibody-drug conjugates, which allows quick production of advanced chemoimmunotherapy cellular therapeutics.

**Background:** Advanced cancer therapies have recently focused on combining chemotherapy and immunotherapy to promote therapeutically beneficial synergy for maximizing the clinical antitumor activity. Effective chemoimmunotherapy requires that (1) chemotherapeutic agents induce cancer cell death and promote immunomodulation, (2) targeted chemotherapy minimizes the adverse effects on immune cells, and (3) immune effector cells maintain their cytolytic activity against cancer cells. New strategies to combine chemotherapy and immunotherapy that meet the above criteria would represent a new platform for the development of targeted cancer chemoimmunotherapy.

**Applications:**

- Cancer chemoimmunotherapy

**Advantages:**

- Kills both metastatic and/or circulating tumor cells
- Enhances the mobilization of immune cells
- Quick production of immune cells conjugated with antibody-drug conjugates

**Contact**

Lisa Lin
Licensing Manager
lisal@tla.arizona.edu
(520) 626-6969
Inventors

Daniel Lee
Postdoctoral Research Associate I, Surgery

David Bull
Professor, Surgery Chief, Cardiothoracic Surgery

Youngwook Won
Assistant Professor, Surgery